Xenon (XENE) Q1 2026 Earnings Call Summary
Xenon Pharmaceuticals reported a significant increase in cash reserves due to a $747.5 million public offering, extending its clinical cash runway into 2029. The company's XTOL-2 trial for AZK showed highly statistically significant results with substantial reductions in focal onset seizures.
Tickers: $XENE
Topics: financial_performance pharmaceuticals seizure_treatment